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University of Washington, Seattle, WashingtonBACKGROUND & AIMS: It is unclear whether a sustained virologic response (SVR) to direct-acting antiviral (DAA)
therapy reduces the risk of incident hepatic encephalopathy (HE) in patients with hepatitis C
virus (HCV) infection or whether it leads to resolution of pre-existent HE.METHODS: We identified 71,457 patients who initiated antiviral treatments in the Veterans Affairs
Healthcare System from January 1, 1999 through December 31, 2015; 35,871 patients (58%)
received only interferon, 4535 patients (7.2%) received DAAs plus interferon, and 21,948 pa-
tients (35%) received DAA-only regimens. We collected data from patients through October 31,
2018, for an average of 6.6 years. We evaluated the association between SVR and the devel-
opment of incident HE or the resolution of pre-existent HE (defined by cessation of pharma-
cotherapy) as well as the risk of hospitalization with HE after adjusting for potential
confounders.RESULTS: Compared to no SVR, SVR after DAA therapy was associated with a significantly lower risk of
developing HE (0.28 vs 1.39 per 100 person-years; adjusted hazard ratio [AHR] 0.41; 95% CI,
0.32–0.51). This association persisted among patients with co-morbid alcohol use disorder and
diabetes as well as patients with cirrhosis (AHR, 0.36; 95% CI, 0.31–0.43) and model for end-
stage liver disease (MELD) scores of 9 or more (AHR, 0.36; 95% CI, 0.30–0.44). SVR was also
associated with reduced risk of hospitalization with HE (AHR, 0.59; 95% CI, 0.43–0.81). Among
2396 patients who were receiving pharmacotherapy for HE at the time of antiviral treatment,
SVR was associated with a significantly increased likelihood of HE resolution for those with
MELD scores below 9 (AHR, 2.26; 95% CI, 1.74–2.93) but not those with MELD scores of 9 or
more.CONCLUSIONS: In a retrospective study of veterans, we found DAA eradication of HCV infection to be associated
with a 59% reduction in risk of development of HE and a > 2-fold increased likelihood of
resolution of pre-existing HE in all subgroups except patients with MELD scores of 9 or more.Keywords: Cirrhosis; Liver Disease; Alcohol; Diabetes.Abbreviations used in this paper: AHR, adjusted hazard ratio; CI, confi-
dence interval; DAA, direct-acting antiviral; HCV, hepatitis C virus; HE,
hepatic encephalopathy; ICD, International Classification of Diseases;
IFN, interferon; MELD, model for end-stage liver disease; SVR, sustained
virologic response; VA, Veterans Affairs.Hepatitis C virus (HCV) is now curable in mostpatients after a short course of direct-acting anti-
viral (DAA) therapy.1 Following HCV eradication, pa-
tients with cirrhosis can experience dramatic
improvements in liver function and short-term out-
comes.2-4 In conjunction with earlier observational data
from the pre-DAA era, these short-term improvements
suggest that curing HCV may reduce the long-term risk
of progressive disease and cirrhosis complications.5
However, controversy persists. Given the short follow-
up of randomized-controlled trials, some have arguedthat the long-term clinical benefits of antiviral treatment
and sustained virologic response (SVR) have not yet been
demonstrated.6 It is therefore imperative to continue to
What You Need to Know
Background
It is unclear whether a sustained virologic response
(SVR) to direct-acting antiviral (DAA) therapy re-
duces the risk of incident hepatic encephalopathy
(HE) in patients with hepatitis C virus (HCV) infec-
tion or whether it leads to resolution of pre-existent
HE.
Findings
In a retrospective study of veterans, we found DAA
eradication of HCV infection to be associated with a
56% reduction in risk of development of HE and a >
2-fold increased likelihood of resolution of pre-
existing HE in all subgroups except patients with
MELD scores of 9 or more
Implications for patient care
Patients with HCV infection should receive DAA
therapy even if they have alcohol-use disorder, dia-evaluate the long-term benefits of DAA-induced SVR in 
observational studies.
Clinicians caring for patients with cirrhosis wish to 
eradicate HCV to prevent, ameliorate, or reverse the 
complications of cirrhosis. Among the complications of 
cirrhosis, none is more devastating than hepatic en-
cephalopathy (HE).7 HE increases the risk of mortality, 
hospitalization, falls, and other injurious accidents while 
simultaneously diminishing quality of life for patients 
and their caregivers.8,9 Interventions that prevent or 
resolve HE would offer substantial value in improving 
the morbidity and public health footprint of cirrhosis. 
Data are lacking regarding the effectiveness of DAA 
therapy with respect to either the prevention of incident 
HE or the resolution of pre-existent HE.
We aimed to determine the associations between HCV 
eradication and the development of incident HE or the 
resolution of pre-existent HE and to investigate such 
factors as disease severity and comorbidities that modify 
these associations in the Veterans Affairs (VA) Health-
care System.betes, cirrhosis, or HE. HCV eradication reduces risk
of HE.Methods
Data Source
The VA Healthcare System is the largest integrated
health care provider of HCV antiviral treatment in the
United States.10 The VA uses a single comprehensive
electronic health care information network that in-
tegrates all care applications into a single, common
database. We obtained data on all patients who initi-
ated antiviral therapy for chronic HCV in the VA system
using the VA Corporate Data Warehouse, a national,
continually updated repository of all aspects of health
care data.11 The study was approved by the Institu-
tional Review Board of the VA Puget Sound Healthcare
System.Study Population
We identified all HCV antiviral regimens (n ¼ 105,362
regimens in 78,940 patients) initiated in the VA during
17 calendar years from January 1, 1999, to December 31,
2015. We defined SVR as a serum HCV RNA viral load
test below the lower limit of detection performed at least
12 weeks after the end of HCV treatment.12 We excluded
6071 patients (7821 regimens) with missing SVR data,
and 1412 patients (2452 regimens) with a prior liver
transplant. The remaining 71,457 patients (95,089 regi-
mens) were included in the study, including 2396 pa-
tients (2815 regimens) who were receiving HE
pharmacotherapy at the time of antiviral treatment and
3627 patients (4813 regimens) who developed HE after
antiviral therapy. The antiviral regimens are detailed in
Supplementary Table 1.Outcome Measures
We explored 3 outcomes (Figure 1): (1) development
of incident HE during follow-up after antiviral treatment,
among patients without evidence of HE before antiviral
treatment; (2) resolution of HE, among patients who
were receiving HE pharmacotherapy at the time they
underwent antiviral treatment; and (3) hospitalization
for HE. We evaluated the risk of hospitalization with HE
and the number of hospitalizations for HE in the 3 years
following therapy for those without baseline HE and
those with treated HE at the time of HCV therapy.
We defined any history of HE before antiviral treat-
ment by the presence of diagnostic codes for HE (Inter-
national Classification of Diseases [ICD]-9 code 572.2 or
ICD-10 code K72.91 or G93.40) recorded at least twice or
use of lactulose, rifaximin, or neomycin (for a duration of
>90 days) at any point before antiviral therapy or up to
90 days after initiation of antiviral therapy.
Incident HE was defined among patients without
prior HE (defined as previously) if identified for the first
time at least 90 days after initiation of antiviral treat-
ment based on ICD-9 code 572.2 or ICD-10 code K72.91
or G93.40 recorded at least twice or the prescription of
lactulose, rifaximin, or neomycin for a duration 90 days
(less if death or transplantation occurred before 90
days), whichever came first. The specificity for HE of the
ICD-9 code 572.2 is 95%–99%.13 As previously stud-
ied,14 we maximized sensitivity for incident HE using
pharmacy linkage for the prescription of medications
that are specific for HE therapy. Whereas chronic rifax-
imin or neomycin use has limited-to-no indications other
than HE, lactulose is only rarely used for constipation.
Figure 1. Study outcomes and definitions.To test the effect of antiviral therapy on resolution of
HE, we focused exclusively on patients with prior HE
who were receiving pharmacologic therapy for HE at the
time of their antiviral treatment, defined by prescriptions
for lactulose, rifaximin, or neomycin covering any time of
the period 90 days before or after antiviral initiation, for
durations 90 days. Resolved HE was defined as the
cessation of prescription fills for HE therapy for 90
days without reinitiation of HE therapy at some point
after antiviral treatment.
Baseline Patient Characteristics
We collected baseline data including age, sex, race/
ethnicity, diabetes, body mass index, HCV genotype, HCV
viral load, and receipt of prior antiviral treatment. We
extracted all clinical factors and laboratory tests before
treatment and recorded the value of each test closest to
the treatment starting date within the preceding 6
months. We defined hepatitis B virus coinfection by
positive hepatitis B virus surface antigen or viral load.
We also determined the presence of cirrhosis, decom-
pensated cirrhosis (ascites, encephalopathy, gastro-
esophageal varices and hepatorenal syndrome), type 2
diabetes mellitus, alcohol use disorders, and substance
use disorders, based on appropriate, validated ICD-9 or
ICD-10 codes recorded at least twice before treatment
initiation in any inpatient or outpatient encounter.15 The
model for end-stage liver disease (MELD) was calculated
as previously described.16
Statistical Analysis
Association between sustained virologic response and
incident hepatic encephalopathy risk. We used Cox pro-
portional hazards regression to compare patients who
achieved SVR with those who did not achieve SVR with
respect to the risk of developing HE. We performed
multivariable adjustment and, in the supplement, a
propensity-matched analysis (using inverse probability
weighting for SVR) and a Fine-Gray model to account forthe competing risk of death. We also performed multiple
Landmark analyses to account for immortal-time bias,
varying cohort entry from 0–90–365 days and end-of-
therapy. Adjustment for potential confounders that may
be associated with both SVR and the risk of progressive
liver disease and HE included type of antiviral treatment,
demographics, hepatic and extrahepatic comorbidities,
and liver disease severity (laboratory values and de-
compensations). Continuous variables were categorized
and modeled as dummy categorical variables.
Follow-up for HE incidence extended until October
31, 2018, so that even the patients treated in late 2015
(ie, the most recent in our cohort) would have substan-
tial follow-up. Patients without incident HE were
censored at the time of death or last follow-up in the VA.
We presented subgroup analyses according to baseline
variables that were associated with progressive liver
disease including markers of disease severity (MELD
score, in increments of 3), alcohol use disorders, dia-
betes, treatment regimens, and the era of antiviral
therapy.
Survival analyses are stratified by the VA facility at
which the antiviral treatment was administered. All
treatments received by a patient during the study period
were analyzed. A significant proportion (23.8%) of pa-
tients received more than 1 antiviral treatment. Patients
who did not achieve SVR were censored at initiation of a
subsequent regimen that led to SVR, if applicable. The
intragroup correlation induced by clustering within pa-
tient was accounted for by using robust variance esti-
mation. Hospitalizations after HCV treatment were
modelled as time-to-event (Cox models) and hospitali-
zations within 3 years of HCV therapy (negative binomial
regression).
Association between sustained virologic response and
resolution of hepatic encephalopathy. Among patients
with pharmacologically treated HE at baseline (defined
as previously), we used multivariable Cox proportional
hazards regression to determine the association between
SVR and resolution of HE (ie, cessation of pharmaco-
therapy) following antiviral treatment after adjusting for
potential confounders, as described previously.
Results
Characteristics of Study Population
All demographics and clinical characteristics are
detailed Table 1. Compared with patients treated with
interferon (IFN) only, those treated with DAA only
were older and more likely to have cirrhosis, hepato-
cellular carcinoma, and alcohol use or substance use
disorders. Overall, patients who achieved SVR were
less likely to have diabetes, cirrhosis, or decom-
pensated cirrhosis.Association Between Sustained Virologic
Response and Incident Hepatic
Encephalopathy
Restricting the treated population to patients
without prior HE, we evaluated the impact of SVR on
the incidence of HE. During a mean follow-up of 6.6
years after antiviral treatment, 3627 out of 71,457
patients developed HE (incidence, 0.77 per 100 patient-Table 1. Baseline Characteristics of HCV-Infected Patients Who
According to Whether They Achieved SVR




(n ¼ 26,406) (n ¼
Age, y (mean [SD]) 55.8 (7.8) 52.4 (6.4) 5
BMI (mean [SD]) 28.2 (5.3) 28.4 (5.2) 2
Male, % 96.6 96.9
Race/ethnicity, %
White, non-Hispanic 55.6 52.1
Black, non-Hispanic 26 26
Hispanic 5.9 6.8
Other 1.7 1.7
Declined to answer/missing 10.8 13.4
Nongenotype 1, % 27.9 27.2
HBV coinfection, % 1 0.6
Cirrhosis, % 16.5 12.7
Decompensated cirrhosis, % 4.3 3.6
Ascites, % 0.5 0.7
Varices, % 3.5 2.2
Hepatocellular carcinoma 1.2 0.3
Diabetes, % 21.4 19.2
Alcohol use disorder, % 38.6 34.7
Substance use disorder, % 31.4 27.1
Laboratory results, mean (SD)
a-Fetoprotein, ng/mL 5.8 (4.1) 6.1 (4.2)
Hemoglobin, g/dL 14.8 (1.5) 15.0 (1.5) 1
Platelet count, k/mL 192.2 (72.4) 197.4 (73.6) 21
Creatinine, mg/dL 1.0 (0.6) 1.0 (0.7)
Bilirubin, g/dL 0.7 (0.5) 0.7 (0.5)
Albumin, g/dL 4.0 (0.5) 4.0 (0.4)
INR 1.1 (1.0) 1.1 (0.9)
MELD 8.0 (3.1) 7.9 (3.0)
DAA, direct-acting antivirals; HBV, hepatitis B virus; IFN, interferon; INR, internat
deviation; SVR, sustained virologic response.years). The timing of HE with respect to treatment
initiation is described in Supplementary Table 2. The
cumulative incidence of HE was lower in patients who
achieved SVR compared with those who did not
(Figure 2A), irrespective of treatment regimen
(Figure 2B). Although SVR is associated with a lower
cumulative incidence and adjusted risk of HE for the
16,395 patients with cirrhosis (adjusted hazard ratio
[AHR], 0.36; 95% confidence interval [CI], 0.31–0.43),
they still experience a substantial residual risk of HE
(Figure 2C). The reduced risk of HE was present for all
regimen types. Effect estimates were similar indepen-
dent of sex; comorbid liver diseases, such as diabetes
and alcohol use disorder; and all baseline MELD scores
(Table 2). These results are also robust to multiple
landmark analyses, varying cohort entry from
0–90–365 from the end-of-therapy, propensity match-
ing, and competing-risks analysis (Supplementary
Tables 3–5). These analyses are further illustrated in
cumulative incidence curves using the matched pop-
ulations in Supplementary Figure 1A–C.
When the risk of HE-related hospitalization was
examined (Supplementary Table 6) we foundReceived Their First Antiviral Treatment From 1999–2015











2.1 (6.8) 57.7 (5.9) 57.3 (6.7) 60.5 (6.9) 61.0 (6.7)
8.2 (5.2) 28.6 (5.3) 28.3 (5.0) 28.5 (5.8) 27.9 (5.4)
95.7 95.6 96.4 98.2 96.6
67.2 50 60 52.7 52.6
12.5 36.3 25.8 31.2 33
5.9 6.1 4.4 6.7 4.9
1.9 1.5 1.4 2 1.7
12.5 6.1 8.4 7.4 7.8
57.3 1.3 4.9 27.9 15.4
1 1.7 1.8 0.9 1.3
7 28.6 21.1 36.2 22.8
1.8 6.6 3.8 13.2 5.6
0.4 0.1 0.1 0.6 0.4
0.9 6.6 3.4 12.9 5.4
0.3 1.7 1 6.3 2.2
13.4 25.3 20.4 31.9 27.4
33.8 41.9 40.7 50.8 44.2
26.2 34.8 32.7 41.5 37.9
4.6 (3.2) 7.8 (4.8) 6.0 (4.1) 7.1 (4.6) 6.0 (4.2)
5.1 (1.4) 14.9 (1.4) 15.0 (1.4) 14.3 (1.7) 14.5 (1.6)
0.9 (69.2) 174.0 (64.6) 187.9 (63.5) 159.0 (74.2) 181.1 (70.7)
1.0 (0.4) 1.0 (0.7) 0.9 (0.3) 1.0 (0.4) 1.0 (0.5)
0.6 (0.4) 0.7 (0.4) 0.6 (0.4) 0.8 (0.7) 0.7 (0.5)
4.1 (0.4) 3.9 (0.5) 4.0 (0.4) 3.7 (0.6) 3.9 (0.5)
1.1 (1.0) 1.2 (1.3) 1.2 (1.1) 1.2 (1.0) 1.2 (0.9)
7.6 (2.7) 7.9 (3.4) 7.6 (3.1) 8.6 (3.4) 8.3 (3.4)
ional normalized ratio; MELD, model for end-stage liver disease; SD, standard
Figure 2. Kaplan-Meier curves comparing the cumulative
incidence of HE development in patients who achieved SVR
versus those who did not, among all patients or clinically
relevant subgroups. (A) All patients. (B) According to antiviral
regimen. (C) According to presence/absence of cirrhosis.substantially reduced risk of a first-hospitalization after
SVR for all treatment types. For example, DAA-alone was
associated with an AHR of 0.59 (95% CI, 0.43–0.81). In
Supplementary Table 7, we examine the total number of
HE-related hospitalizations in the 3 years following HCV
therapy. Again SVR is associated with reduced risk of
hospitalization, adjusted incidence-rate ratio of 0.70
(95% CI, 0.52–0.94).Association Between Sustained Virologic
Response and Resolution of Hepatic
Encephalopathy
Among 2396 patients who were receiving HE phar-
macotherapy at the time of antiviral treatment, 881
(36.8%) achieved HE resolution (defined as cessation of
pharmacotherapy) during a mean follow-up of 3.1 years
after antiviral treatment. Patients who achieved SVR
were significantly more likely to experience resolution of
HE than patients who did not achieve SVR (AHR, 1.61;
95% CI, 1.24–2.10) (Table 3, Figure 3A). SVR was asso-
ciated with a higher likelihood of HE resolution among
many clinically relevant subgroups, such as patients with
and without diabetes and alcohol use disorder. These
data were consistent irrespective of the specific treat-
ment used for HE. IFN-induced SVR seemed to be more
strongly associated with HE resolution (AHR, 2.10; 95%
CI, 1.57–2.82) than DAA þ IFN-induced SVR (AHR, 1.39;
95% CI, 0.60–3.18) or DAA-induced SVR (AHR, 1.39;
95% CI, 1.03–1.87) (Table 3, Figure 3B). SVR was also
associated with a higher likelihood of HE resolution
among patients with MELD <9 (AHR, 2.26; 95% CI,
1.74–2.93) but, importantly, not among patients with
MELD 9 (AHR, 1.16; 95%, 0.84–1.60) (Figure 3C).
However, we suspect that DAA-induced SVR is associated
with a lower effect estimate because these therapies
were used in a sicker population. Indeed, when the
subset of patients with MELD <9 who received DAA was
examined, SVR was associated with an AHR for the res-
olution of HE of 2.20 (95% CI, 1.36–3.57). After pro-
pensity matching in Supplementary Table 8, SVR
remained associated with resolved HE after IFN; how-
ever, the CI widened for DAA-alone (AHR, 1.28; 95% CI,
0.95–1.74). Conversely, when accounting for the
competing risk of death in Supplementary Table 9, the
association between SVR and resolved HE strengthened
(AHR, 1.51; 95% CI, 1.13–2.01). These relationships are
further illustrated in the cumulative incidence curves in
Supplementary Figure 2A–C.
We next evaluated the impact of SVR on time-to-
hospitalization (Supplementary Table 10) and the total
number of hospitalizations after HCV therapy
(Supplementary Table 11) for patients with treated HE at
baseline. We find that SVR is associated with reduced
risk of first-hospitalization for IFN (AHR, 0.53; 95% CI,
0.35–0.83) but not DAA (AHR, 0.79; 95% CI, 0.57–1.10).
Similar trends are seen for the total burden of hospital-
izations with respective incidence-rate ratio for IFN and
DAA of 0.28 (95% CI, 0.19–0.41) and 0.80 (95% CI,
0.60–1.07).Discussion
Long-term data regarding the impact of HCV eradi-
cation on important clinical outcomes are limited among
real-world patients. Of particular importance is the risk




















IFN-only regimens No SVR 34,006(66.7) 8.6 3,613(10.6) 1.24 1 1
SVR 16,973 (33.3) 10.6 508 (3.0) 0.28 0.23 (0.21–0.26) 0.26 (0.23–0.30)
DAA þ IFN
regimens
No SVR 3198 (42.4) 3.3 132 (4.1) 1.26 1 1
SVR 4345 (57.6) 5.2 74 (1.7) 0.33 0.27 (0.20–0.37) 0.31 (0.22–0.43)
DAA-only regimens No SVR 3336 (10.2) 2.7 124 (3.7) 1.39 1 1
SVR 29,414 (89.8) 3.2 362 (1.2) 0.39 0.28 (0.22–0.35) 0.41 (0.32–0.51)
Cirrhosis No SVR 6940 (42.3) 5.2 1302 (18.8) 3.6 1 1
SVR 9455 (57.7) 4.2 419 (4.4) 1.05 0.29 (0.25–0.32) 0.36 (0.31–0.43)
No cirrhosis No SVR 33,600 (44.9) 8.2 2567 (7.6) 0.93 1 1
SVR 41,277 (55.1) 6.2 525 (1.3) 0.2 0.23 (0.20–0.25) 0.25 (0.22–0.28)
Men No SVR 39,311 (44.6) 7.7 3771 (9.6) 1.25 1 1
SVR 48,862 (55.4) 5.8 905 (1.9) 0.32 0.25 (0.23–0.28) 0.26 (0.23–0.28)
Women No SVR 1209 (39.5) 8.2 91 (7.5) 0.91 1 1
SVR 1855 (60.5) 6.4 39 (2.1) 0.33 0.34 (0.22–0.51) 0.35 (0.20–0.62)
Diabetes No SVR 8800 (42.9) 6.9 936 (10.6) 1.55 1 1
SVR 11,731 (57.1) 4.7 288 (2.5) 0.52 0.33 (0.29–0.39) 0.36 (0.30–0.44)
No diabetes No SVR 31,740 (44.9) 7.9 2933 (9.2) 1.17 1 1
SVR 39,001 (55.1) 6.2 656 (1.7) 0.27 0.23 (0.21–0.26) 0.26 (0.23–0.30)
Alcohol use disorder No SVR 14,647 (42.0) 7.0 1393 (9.5) 1.36 1 1
SVR 20,226 (58.0) 5.3 406 (2.0) 0.38 0.27 (0.24–0.31) 0.31 (0.27–0.37)
No alcohol use
disorder
No SVR 25,893 (45.9) 8.1 2476 (9.6) 1.19 1 1
SVR 30,506 (54.1) 6.2 538 (1.8) 0.28 0.24 (0.22–0.27) 0.27 (0.23–0.31)
Pre-2009 No SVR 27,308 (68.5) 9.4 3216 (11.8) 1.25 1 1
SVR 12,583 (31.5) 11.8 407 (3.2) 0.27 0.22 (0.20–0.25) 0.25 (0.21–0.29)
2009–2015 No SVR 13,232 (25.8) 4.1 653 (4.9) 1.19 1 1
SVR 38,149 (74.2) 3.9 537 (1.4) 0.36 0.29 (0.26–0.33) 0.30 (0.26–0.34)
MELD <9 No SVR 28,555 (43.0) 7.6 2348 (8.2) 1.08 1 1
SVR 37,820 (57.0) 5.7 552 (1.5) 0.25 0.24 (0.22–0.27) 0.27 (0.24–0.30)
MELD 9 No SVR 4759 (42.4) 6.2 765 (16.1) 2.6 1 1
SVR 6455 (57.6) 4.7 246 (3.8) 0.82 0.29 (0.25–0.34) 0.36 (0.30–0.44)
MELD 12 No SVR 1881 (39.8) 5.5 303 (16.1) 2.92 1 1
SVR 2849 (60.2) 4.2 126 (4.4) 1.06 0.34 (0.27–0.42) 0.39 (0.29–0.52)
MELD 15 No SVR 860 (38.6) 5.8 100 (11.6) 2.02 1 1
SVR 1366 (61.4) 4.3 47 (3.4) 0.8 0.39 (0.26–0.58) 0.48 (0.30–0.76)
MELD 18 No SVR 591 (42.1) 6.0 66 (11.2) 1.87 1 1
SVR 812 (57.9) 4.4 19 (2.3) 0.53 0.29 (0.17–0.49) 0.30 (0.14–0.61)
MELD 21 No SVR 304 (41.7) 6.3 31 (10.2) 1.63 1 1
SVR 425 (58.3) 4.8 8 (1.9) 0.39 0.25 (0.11–0.56) 0.34 (0.09–1.26)
CI, confidence interval; DAA, direct-acting antivirals; HE, hepatic encephalopathy; IFN, interferon; MELD, model for end-stage liver disease; SVR, sustained
virologic response.
aAdjusted for regimen type, cirrhosis, decompensated cirrhosis, age, sex, race/ethnicity, body mass index, hepatitis B virus coinfection, type 2 diabetes mellitus,
ascites, varices, hepatocellular carcinoma, alcohol use disorders, substance use disorder, platelet count, serum bilirubin, serum creatinine, serum albumin, in-
ternational normalized ratio, and blood hemoglobin levels. The laboratory tests were categorized into quartiles and modeled as dummy categorical variables.of HE. HE is a watershed moment in the natural history
of chronic HCV, one after which morbidity and mortality
sharply rises.8,9,17-19 Accordingly, there are broad socie-
tal benefits tied to interventions that can prevent or
resolve HE. To evaluate the impact of SVR on the risk of
HE, we examined a very large sample from the VA
Healthcare System (>70,000 patients, including roughly
25,000 who received DAA only) with long-term follow-
up (>6.5 years per-person). We show that SVR after DAA
therapy is associated with a 59% reduction in the risk of
incident HE and a 41% reduction in the risk of hospi-
talization with HE. When HE is present at the time of
therapy, SVR is associated with a 61% increased rate of
HE resolution.Sustained Virologic Response Reduces the
Risk of Hepatic Encephalopathy
Intensive therapy for HE is associated with incon-
sistent benefits. Even patients receiving optimal treat-
ment experience breakthrough episodes and
diminished quality of life.20,21 Treating the underlying
liver disease in the hope of forestalling or reducing
further progression to cirrhosis and HE is therefore the
best option to reduce HE-related risks. Our data suggest
that SVR is associated with a dramatic reduction in the
risk of developing HE. This includes reductions of 75%
for those without cirrhosis at baseline; 64% for those
with cirrhosis; and equivalent reductions for those with
















IFN-only regimens No SVR 811 (82.4) 4.8 289 (35.6) 7.47 1 1
SVR 173 (17.6) 4.1 113 (65.3) 15.76 2.08 (1.62–2.68) 2.10 (1.57–2.82)
DAA þ IFN regimens No SVR 114 (57.6) 2.4 24 (21.1) 8.68 1 1
SVR 84 (42.4) 3.0 41 (48.8) 16.27 1.88 (1.12–3.16) 1.39 (0.60–3.18)
DAA-only regimens No SVR 366 (22.4) 1.9 63 (17.2) 9 1 1
SVR 1267 (77.6) 2.4 432 (34.1) 14.26 1.59 (1.21–2.09) 1.39 (1.03–1.87)
MELD <9 No SVR 768 (51.1) 4.4 253 (32.9) 7.56 1 1
SVR 734 (48.9) 2.7 357 (48.6) 17.99 2.27 (1.89–2.72) 2.26 (1.74–2.93)
MELD 9 No SVR 670 (42.7) 3.2 164 (24.5) 7.66 1 1
SVR 898 (57.3) 2.6 274 (30.5) 11.74 1.49 (1.20–1.84) 1.16 (0.84–1.60)
DAA-only No SVR 120 (20.1) 2.1 21 (17.5) 8.18 1 1
MELD <9 SVR 476 (79.9) 2.3 212 (44.5) 19.27 2.35 (1.49–3.70) 2.20 (1.36–3.57)
DAA-only No SVR 224 (23.7) 1.8 40 (17.9) 10.02 1 1
MELD 9 SVR 722 (76.3) 2.4 199 (27.6) 11.34 1.13 (0.79–1.61) 0.98 (0.66–1.45)
Diabetes No SVR 410 (41.7) 3.5 115 (28.0) 8 1 1
SVR 574 (58.3) 2.5 208 (36.2) 14.71 1.80 (1.39–2.34) 1.95 (1.27–2.97)
No diabetes No SVR 881 (48.1) 3.9 261 (29.6) 7.66 1 1
SVR 950 (51.9) 2.7 378 (39.8) 14.63 1.86 (1.56–2.22) 1.75 (1.37–2.24)
Alcohol use disorder No SVR 654 (43.2) 3.6 186 (28.4) 8 1 1
SVR 859 (56.8) 2.6 297 (34.6) 13.28 1.63 (1.33–2.00) 1.43 (1.08–1.90)
No alcohol use disorder No SVR 637 (48.9) 4.0 190 (29.8) 7.54 1 1
SVR 665 (51.1) 2.6 289 (43.5) 16.4 2.10 (1.71–2.58) 2.29 (1.71–3.06)
Pre-2009 No SVR 631 (85.0) 5.2 232 (36.8) 7.11 1 1
SVR 111 (15.0) 4.5 71 (64.0) 14.14 1.95 (1.43–2.65) 2.17 (1.49–3.15)
2009–2015 No SVR 660 (31.8) 2.4 144 (21.8) 9.09 1 1
SVR 1413 (68.2) 2.5 515 (36.4) 14.73 1.59 (1.30–1.94) 1.71 (1.38–2.12)
Men No SVR 1253 (46.0) 3.7 364 (29.1) 7.8 1 1
SVR 1470 (54.0) 2.6 568 (38.6) 14.81 1.85 (1.59–2.14) 2.06 (1.73–2.46)
Women No SVR 39 (41.9) 4.7 13 (33.3) 7.02 1 1
SVR 54 (58.1) 3.0 18 (33.3) 11 1.80 (0.85–3.82) 11.3 (0.78–164.5)
Ascites  varices 
HRS
No SVR 447 (40.2) 2.7 79 (17.7) 6.43 1 1
SVR 665 (59.8) 2.5 188 (28.3) 11.28 1.75 (1.32–2.32) 1.82 (1.18–2.80)
All regimens, lactulose
or rifaximin, but not
neomycin
No SVR 1268 (45.5) 3.8 370 (29.2) 7.77 1 1
SVR 1521 (54.5) 2.6 585 (38.5) 14.65 1.84 (1.59–2.13) 1.78 (1.44–2.20)
All regimens, lactulose
alone
No SVR 1044 (51.6) 4.1 346 (33.1) 8.1 1 1
SVR 980 (48.4) 2.6 467 (47.7) 18.09 2.13 (1.82–2.49) 1.84 (1.47–2.29)
All regimens, rifaximin
alone
No SVR 51 (27.1) 2.1 8 (15.7) 7.5 1 1
SVR 137 (72.9) 2.3 59 (43.1) 18.89 2.57 (1.14–5.78) 1.85 (0.44–7.85)
CI, confidence interval; DAA, direct-acting antivirals; HE, hepatic encephalopathy; HRS, hepatorenal syndrome; IFN, interferon; MELD, model for end-stage liver
disease; SVR, sustained virologic response.
aAdjusted for regimen type, cirrhosis, decompensated cirrhosis, age, sex, race/ethnicity, body mass index, hepatitis B virus coinfection, type 2 diabetes mellitus,
ascites, varices, hepatocellular carcinoma, alcohol use disorders, substance use disorder, platelet count, serum bilirubin, serum creatinine, serum albumin, in-
ternational normalized ratio, and blood hemoglobin levels. The laboratory tests were categorized into quartiles and modeled as dummy categorical variables.MELD 9, comorbid alcohol use disorder, and diabetes.
These data are bolstered further by a marked reduction
in the risk and overall burden of hospitalization with
HE.Sustained Virologic Response Increases the
Likelihood of Hepatic Encephalopathy
Resolution
After an episode of overt HE, especially after
repeated episodes,22 it is unclear whether it is possible
to safely discontinue HE therapy without risk ofrecurrence. Guidelines from the American Association
for the Study of Liver Disease acknowledge that data
are lacking for this important question but suggest that
if liver function improves substantially, a trial of
treatment discontinuation could be considered.22
Addressing this gap, we add novel data to show that
among patients with treated HE at the time of HCV
therapy, SVR is associated with a significantly increased
likelihood of successfully discontinuing HE therapy
without recurrence, particularly for patients with MELD
score <9. SVR is also associated with fewer hospitali-
zations with HE. Unfortunately, patients with MELD >9
do not experience this benefit after SVR, suggesting that
Figure 3. Cumulative probability curves comparing the reso-
lution of HE in patients with SVR versus those without SVR
among all patients or clinically relevant subgroups. (A) All
patients. (B) By antiviral regimen. (C) By MELD category.there is a disease severity threshold after which
freedom from HE therapy is unlikely. It is known that
SVR is associated with improved quality of life.23 Min-
imal HE is associated with and may even be confused
for poor patient-reported outcomes. Accordingly, the
reasons underlying the clinical decision to discontinue
HE therapy are challenging to discern even prospec-
tively. It is clear, however, that SVR was associated with
durably discontinuing HE therapy.What Is Known About the Risk of Hepatic
Encephalopathy After Hepatitis C Virus
Therapy?
Our findings extend the data on the impact of HCV
therapy on HE risk in multiple ways. First, we demon-
strate a reduced risk of HE after DAA-induced SVR (and
IFN-induced SVR) in a contemporary dataset with long
follow-up, after adjustment for liver disease severity and
comorbid liver diseases, such as diabetes and alcohol use
disorder. This dataset is also the largest to explore the
association of SVR with HE. Previously, van der Meer
et al5 showed that after HCV therapy, 11 (2.7%) patients
without SVR developed overt HE in follow-up compared
with 0 (of 125) matched patients with SVR. Because the
decision to use IFN and IFN-associated SVR are both
associated with favorable baseline characteristics that
may also be associated with lower risk of developing HE,
our adjusted DAA-associated outcomes are likely more
applicable to today’s patients with HCV. Clinical trials of
DAA in compensated patients or those with early liver
disease lack sufficient follow-up to determine associa-
tions with HE risk. Two clinical trials of DAAs have
included patients with decompensated cirrhosis, both of
which demonstrated improved MELD and Child-Pugh
scores but lacked long-term follow-up beyond 24
weeks.3,4
Second, we show that SVR is associated with
increased likelihood of a durable long-term resolution of
HE defined by cessation of HE therapy for all patients
save for those with MELD scores 9. These data extend a
recently published combined analysis of the trials of
sofosbuvir-based DAA therapy in patients with decom-
pensated cirrhosis. El-Sherif et al2 showed that subjects
with HE were among those least likely to benefit from
DAA therapy after 12–24 weeks of follow-up. These au-
thors demonstrated that those with HE at baseline were
most likely to experience the suboptimal outcome known
as “MELD purgatory” whereby their MELD would
improve (to <15) but they would retain persistent
HE.2,24 Our study’s design of much longer follow-up
(3.14 years vs 24 weeks) and sensitive outcome deter-
mination (cessation of therapy) is more broadly appli-
cable to real-world patients. Although SVR was
associated with reduced HE-related hospitalizations, the
association was not statistically significant when evalu-
ating DAAs separately.Limitations
These data must be interpreted in the context of the
study design. First, patients were derived from a single,
national health care system with fairly uniform antiviral
treatment practices and guidelines across its facilities.
Second, because this is by necessity an observational
study (patients cannot be randomized to eradication or
not and cannot ethically be randomized to antiviral
9, which is biologically plausible and enhances the in-
ternal validity of the study. Third, we defined resolved
HE as the cessation of therapy (without reinitiation
during follow-up), if overt HE recurred (particularly in
patients who previously received HE-therapy) they
would likely universally have been restarted on HE
therapy. We cannot, with these data, determine whether
patients with “resolved HE” retained cognitive dysfunc-
tion or minimal HE. Fourth and similarly, we only
measured diagnosed HE (using diagnostic codes and
medical therapy). Because we did not assess cognition,
these data do not evaluate the risk of minimal HE or
changes in cognitive performance after HCV therapy.
Finally, the definition of HE was based in part on chronic
lactulose use. Some patients may be placed on this
medication exclusively to treat constipation and not HE.
Conclusions
These data from a large cohort of patients undergoing
HCV therapy, including roughly 25,000 who received
DAA alone, with and without cirrhosis, and who were
followed for many years after therapy demonstrates 2
core benefits associated with SVR. First, patients
achieving SVR are significantly less likely to experience
incident HE. Second, for patients with actively treated HE
at the time of HCV therapy, SVR is associated with
significantly improved likelihood of HE resolution for all
clinically relevant subgroups except patients with MELD
9. Taken together, these data demonstrate a specific
benefit of HCV therapy and one that may reduce the
national burden of HE and its related complications.
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treatment versus no treatment, especially with long-term 
follow-up) we cannot exclude the possibility that resid-
ual confounding may have contributed to the associa-
tions we observed between SVR and prevention or 
resolution of HE. However, the associations persisted 
after careful adjustment for 20 baseline characteristics 
known or suspected to be associated with SVR and HE. 
Furthermore, the associations persisted across almost all 
subgroups, except for the lack of association between 
SVR and HE resolution among patients with MELD scoreReferences
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Supplementary Figure 1. Kaplan-Meier curves comparing the cumulative incidence of HE development in patients who
achieved SVR versus those who did not, among all patients or clinically relevant subgroups. Left plots use inverse probability
weights based on the propensity scores. Plots on the right use trimmed (largest and smallest propensity scores dropped)
inverse probability weights. (A) All patients. (B) According to antiviral regimen. (C) According to presence/absence of cirrhosis.
Supplementary Figure 2. Cumulative-probability curves comparing the resolution of HE in patients with SVR versus those
without SVR among all patients or clinically relevant subgroups. Left plots use inverse probability weights based on the
propensity scores. Plots on the right use trimmed (largest and smallest propensity scores dropped) inverse probability weights.
(A) All patients. (B) By antiviral regimen. (C) By MELD category.
Supplementary Table 1. Types of HCV Antiviral Treatment Regimens Included in Our Study of VA Patients From 1999–2015
Treatment category Regimena First regimen, n (%) All regimens, n (%)
IFN only Interferon 3872 (5.4) 5914 (6.2)
PEG 36,991 (51.8) 46,245 (48.6)
DAA þ IFN Boceprevir þ PEG 3185 (4.5) 4968 (5.2)
Telaprevir þ PEG 498 (0.7) 997 (1.0)
Simeprevir þ PEG 14 (0.0) 23 (0.0)
Sofosbuvir þ PEG 1046 (1.5) 1834 (1.9)
DAA only Sofosbuvir  daclatasvir 3473 (4.9) 4636 (4.9)
Sofosbuvir þ simeprevir 2068 (2.9) 3331 (3.5)
Ledipasvir/sofosbuvir 15,055 (21.1) 20,539 (21.6)
Paritaprevir/ritonavir/ombitasvir/dasabuvir 5255 (7.4) 6602 (6.9)
DAA, direct-acting antivirals; HCV, hepatitis C virus; IFN, interferon; PEG, pegylated interferon; VA, Veterans Affairs.
aRegimens with or without ribavirin were included together.

























IFN 4270 149 (3.5) 283 (6.6) 526 (12.3) 235 (5.5)
IFN þ DAA 234 28 (12.0) 50 (21.4) 86 (36.8) 44 (18.8)
DAA 601 115 (19.1) 175 (29.1) 291 (48.4) 113 (18.8)
SVR 1056 112 (10.6) 187 (17.7) 319 (30.2) 159 (15.1)
No SVR 4049 180 (4.4) 321 (7.9) 584 (14.4) 233 (5.8)
DAA, direct-acting antivirals; HE, hepatic encephalopathy; IFN, interferon; SVR, sustained virologic response.




















Analysis starting at 90 d from antiviral treatment initiation
IFN-only
regimens
No SVR 34,006 (66.7) 8.6 3,613 (10.6) 1.24 1 1
SVR 16,973 (33.3) 10.6 508 (3.0) 0.28 0.23 (0.21–0.26) 0.26 (0.23–0.30)
DAA þ IFN
regimens
No SVR 3198 (42.4) 3.3 132 (4.1) 1.26 1 1
SVR 4345 (57.6) 5.2 74 (1.7) 0.33 0.27 (0.20–0.37) 0.31 (0.22–0.43)
DAA-only
regimens
No SVR 3336 (10.2) 2.7 124 (3.7) 1.39 1 1
SVR 29,414 (89.8) 3.2 362 (1.2) 0.39 0.28 (0.22–0.35) 0.41 (0.32–0.51)
Analysis starting at 180 d from antiviral treatment initiation
IFN-only
regimens
No SVR 33,897 (66.7) 8.6 3504 (10.3) 1.2 1 1
SVR 16,948 (33.3) 10.6 483 (2.8) 0.27 0.22 (0.20–0.25) 0.25 (0.22–0.28)
DAA þ IFN
regimens
No SVR 3182 (42.3) 3.3 116 (3.6) 1.1 1 1
SVR 4339 (57.7) 5.2 68 (1.6) 0.3 0.27 (0.20–0.37) 0.30 (0.22–0.43)
DAA-only
regimens
No SVR 3320 (10.2) 2.7 108 (3.3) 1.21 1 1
SVR 29,370 (89.8) 3.2 318 (1.1) 0.34 0.28 (0.22–0.35) 0.39 (0.31–0.50)
Analysis starting at 360 d from antiviral treatment initiation
IFN-only
regimens
No SVR 33,697 (66.6) 8.7 3304 (9.8) 1.13 1 1
SVR 16,905 (33.4) 10.6 440 (2.6) 0.24 0.21 (0.19–0.24) 0.24 (0.21–0.27)
DAA þ IFN
regimens
No SVR 3160 (42.2) 3.3 94 (3.0) 0.9 1 1
SVR 4325 (57.8) 5.2 54 (1.2) 0.24 0.24 (0.17–0.34) 0.26 (0.18–0.38)
DAA-only
regimens
No SVR 3279 (10.1) 2.7 67 (2.0) 0.75 1 1
SVR 29,295 (89.9) 3.2 243 (0.8) 0.26 0.33 (0.25–0.44) 0.43 (0.32–0.59)
Analysis starting at the time antiviral treatment was stopped
IFN-only
regimens
No SVR 33,917 (66.7) 8.6 3524 (10.4) 1.21 1 1
SVR 16,943 (33.3) 10.6 478 (2.8) 0.27 0.22 (0.20–0.25) 0.25 (0.22–0.28)
DAA þ IFN
regimens
No SVR 3189 (42.4) 3.3 123 (3.9) 1.17 1 1
SVR 4335 (57.6) 5.2 64 (1.5) 0.28 0.24 (0.18–0.33) 0.28 (0.20–0.39)
DAA-only
regimens
No SVR 3335 (10.2) 2.7 123 (3.7) 1.37 1 1
SVR 29,401 (89.8) 3.2 349 (1.2) 0.37 0.27 (0.22–0.34) 0.39 (0.31–0.49)
CI, confidence interval; DAA, direct-acting antivirals; HE, hepatic encephalopathy; IFN, interferon; SVR, sustained virologic response.
























No SVR 1 1 1 1 1 1
SVR 0.23 (0.21–0.26) 0.26 (0.23–0.30) 0.26 (0.23–0.30) 0.26 (0.23–0.30) 0.26 (0.23–0.30) 0.26 (0.23–0.30)
DAA þ IFN
regimens
No SVR 1 1 1 1 1 1
SVR 0.27 (0.20–0.37) 0.32 (0.22–0.43) 0.32 (0.23–0.44) 0.31 (0.22–0.43) 0.30 (0.22–0.42) 0.30 (0.21–0.42)
DAA-only
regimens
No SVR 1 1 1 1 1 1
SVR 0.28 (0.22–0.35) 0.41 (0.32–0.51) 0.35 (0.27–0.44) 0.43 (0.34–0.54) 0.32 (0.25–0.41) 0.42 (0.33–0.53)
CI, confidence interval; DAA, direct-acting antivirals; HE, hepatic encephalopathy; IFN, interferon; IPW, inverse probability weights; SVR, sustained virologic
response.
aAdjusted for regimen type, cirrhosis, decompensated cirrhosis, age, sex, race/ethnicity, body mass index, hepatitis B virus coinfection, type 2 diabetes mellitus,
ascites, varices, hepatocellular carcinoma, alcohol use disorders, substance use disorder, platelet count, serum bilirubin, serum creatinine, serum albumin,
international normalized ratio, and blood hemoglobin levels. The laboratory tests were categorized into quartiles and modeled as dummy categorical variables.
bIPW based on propensity score estimates. Trimmed weights drop the largest and smallest 1% of propensity scores.
















No SVR 1 1 1 1
SVR 0.23 (0.21–0.26) 0.26 (0.23–0.30) 0.24 (0.22–0.27) 0.29 (0.26–0.32)
DAA þ IFN
regimens
No SVR 1 1 1 1
SVR 0.27 (0.20–0.37) 0.31 (0.22–0.43) 0.28 (0.21–0.38) 0.33 (0.24–0.46)
DAA-only
regimens
No SVR 1 1 1 1
SVR 0.28 (0.22–0.35) 0.41 (0.32–0.51) 0.29 (0.24–0.35) 0.43 (0.35–0.54)
CI, confidence interval; DAA, direct-acting antivirals; HE, hepatic encephalopathy; IFN, interferon; SVR, sustained virologic response.
aAdjusted for regimen type, cirrhosis, decompensated cirrhosis, age, sex, race/ethnicity, body mass index, hepatitis B virus coinfection, type 2 diabetes mellitus,
ascites, varices, hepatocellular carcinoma, alcohol use disorders, substance use disorder, platelet count, serum bilirubin, serum creatinine, serum albumin,
international normalized ratio, and blood hemoglobin levels. The laboratory tests were categorized into quartiles and modeled as dummy categorical variables.
bWith death as a competing risk.























No SVR 34,006 (66.7) 8.9 1948 (5.7) 0.65 1 1
SVR 16,973 (33.3) 10.7 292 (1.7) 0.16 0.24 (0.21–0.28) 0.28 (0.24–0.33)
DAA þ IFN
regimens
No SVR 3198 (42.4) 3.3 43 (1.3) 0.4 1 1
SVR 4345 (57.6) 5.2 39 (0.9) 0.17 0.39 (0.26–0.61) 0.43 (0.26–0.70)
DAA-only
regimens
No SVR 3336 (10.2) 2.7 54 (1.6) 0.6 1 1
SVR 29,414(89.8) 3.2 298 (1.0) 0.32 0.52 (0.38–0.70) 0.59 (0.43–0.81)
CI, confidence interval; DAA, direct-acting antivirals; HE, hepatic encephalopathy; IFN, interferon; SVR, sustained virologic response.
aAdjusted for regimen type, cirrhosis, decompensated cirrhosis, age, sex, race/ethnicity, body mass index, hepatitis B virus coinfection, type 2 diabetes mellitus,
ascites, varices, hepatocellular carcinoma, alcohol use disorders, substance use disorder, platelet count, serum bilirubin, serum creatinine, serum albumin,
international normalized ratio, and blood hemoglobin levels. The laboratory tests were categorized into quartiles and modeled as dummy categorical variables.
Supplementary Table 7. Association Between SVR and the Number of Hospitalizations in the First 3 Years After Treatment








hospitalizations for HE (SD)








No SVR 34,006 (66.7) 0.14 (0.77) 1 1
SVR 16,973 (33.3) 0.03 (0.32) 0.22 (0.17–0.28) 0.25 (0.21–0.31)
DAA þ IFN
regimens
No SVR 3198 (42.4) 0.03 (0.29) 1 1
SVR 4345 (57.6) 0.01 (0.12) 0.34 (0.21–0.55) 0.59 (0.38–0.92)
DAA-only
regimens
No SVR 3336 (10.2) 0.02 (0.15) 1 1
DAA, direct-acting antivirals; HE, hepatic encephalopathy; IFN, interferon; SD, standard deviation; SVR, sustained virologic response.
























No SVR 1 1 1 1 1 1
SVR 2.08 (1.62–2.68) 2.10 (1.57–2.82) 2.24 (1.70–2.97) 2.32 (1.76–3.07) 2.01 (1.50–2.68) 2.09 (1.55–2.81)
DAA þ IFN
regimens
No SVR 1 1 1 1 1 1
SVR 1.88 (1.12–3.16) 1.39 (0.60–3.18) 1.86 (1.02–3.39) 1.34 (0.56–3.18) 2.09 (1.17–3.75) 1.39 (0.58–3.30)
DAA-only
regimens
No SVR 1 1 1 1 1 1
SVR 1.59 (1.21–2.09) 1.39 (1.03–1.87) 1.53 (1.13–2.07) 1.28 (0.95–1.72) 1.59 (1.17–2.15) 1.28 (0.95–1.74)
CI, confidence interval; DAA, direct-acting antivirals; HE, hepatic encephalopathy; IFN, interferon; IPW, inverse probability weights; SVR, sustained virologic
response.
aAdjusted for regimen type, cirrhosis, decompensated cirrhosis, age, sex, race/ethnicity, body mass index, hepatitis B virus coinfection, type 2 diabetes mellitus,
ascites, varices, hepatocellular carcinoma, alcohol use disorders, substance use disorder, platelet count, serum bilirubin, serum creatinine, serum albumin,
international normalized ratio, and blood hemoglobin levels. The laboratory tests were categorized into quartiles and modeled as dummy categorical variables.
bIPW based on propensity score estimates. Trimmed weights drop the largest and smallest 1% of propensity scores.
















No SVR 1 1 1 1
SVR 2.08 (1.62–2.68) 2.10 (1.57–2.82) 2.32 (1.86–2.91) 2.26 (1.73–2.96)
DAA þ IFN
regimens
No SVR 1 1 1 1
SVR 1.88 (1.12–3.16) 1.39 (0.60–3.18) 1.99 (1.21–3.28) 1.40 (0.63–3.15)
DAA-only
regimens
No SVR 1 1 1 1
SVR 1.59 (1.21–2.09) 1.39 (1.03–1.87) 1.75 (1.34–2.29) 1.51 (1.13–2.01)
CI, confidence interval; DAA, direct-acting antivirals; HE, hepatic encephalopathy; IFN, interferon; SVR, sustained virologic response.
aAdjusted for regimen type, cirrhosis, decompensated cirrhosis, age, sex, race/ethnicity, body mass index, hepatitis B virus coinfection, type 2 diabetes mellitus,
ascites, varices, hepatocellular carcinoma, alcohol use disorders, substance use disorder, platelet count, serum bilirubin, serum creatinine, serum albumin,
international normalized ratio, and blood hemoglobin levels. The laboratory tests were categorized into quartiles and modeled as dummy categorical variables.
bWith death as a competing risk.
Supplementary Table 10. Association Between SVR and the Risk of Hospitalization With HE, Among Patients Who Were on























No SVR 983 (83.3) 5.9 239 (24.3) 4.12 1 1
SVR 197 (16.7) 8.4 28 (14.2) 1.69 0.44 (0.28–.69) 0.53 (0.35–0.83)
DAA þ IFN
regimens
No SVR 167 (59.9) 2.8 25 (15.0) 5.37 1 1
SVR 112 (40.1) 4.4 10 (8.9) 2.03 0.44 (0.20–0.99) 0.52 (0.15–1.83)
DAA-only
regimens
No SVR 497 (21.1) 2.1 58 (11.7) 5.59 1 1
SVR 1,861 (78.9) 2.9 179 (9.6) 3.35 0.67 (0.49–0.91) 0.79 (0.57–1.10)
CI, confidence interval; DAA, direct-acting antivirals; HE, hepatic encephalopathy; IFN, interferon; SVR, sustained virologic response.
aAdjusted for regimen type, cirrhosis, decompensated cirrhosis, age, sex, race/ethnicity, body mass index, hepatitis B virus coinfection, type 2 diabetes mellitus,
ascites, varices, hepatocellular carcinoma, alcohol use disorders, substance use disorder, platelet count, serum bilirubin, serum creatinine, serum albumin,
international normalized ratio, and blood hemoglobin levels. The laboratory tests were categorized into quartiles and modeled as dummy categorical variables.
Supplementary Table 11. Association Between SVR and Number of Hospitalizations in the First 3 Years After Treatment Start








hospitalizations for HE (SD)








No SVR 983 (83.3) 0.84 (2.09) 1 1
SVR 197 (16.7) 0.31 (1.17) 0.38 (0.17–0.84) 0.28 (0.19–0.41)
DAA þ IFN
regimens
No SVR 167 (59.9) 0.29 (0.79) 1 1
SVR 112 (40.1) 0.14 (0.55) 0.49 (0.21–1.12) 0.56 (0.25–1.26)
DAA-only
regimens
No SVR 497 (21.1) 0.28 (0.89) 1 1
SVR 1,861 (78.9) 0.19 (0.67) 0.70 (0.51–0.96) 0.80 (0.60–1.07)
DAA, direct-acting antivirals; HE, hepatic encephalopathy; IFN, interferon; SD, standard deviation; SVR, sustained virologic response.
aAdjusted for regimen type, cirrhosis, decompensated cirrhosis, age, sex, race/ethnicity, body mass index, hepatitis B virus coinfection, type 2 diabetes mellitus,
ascites, varices, hepatocellular carcinoma, alcohol use disorders, substance use disorder, platelet count, serum bilirubin, serum creatinine, serum albumin,
international normalized ratio, and blood hemoglobin levels. The laboratory tests were categorized into quartiles and modeled as dummy categorical variables.
